Villya Announces Breakthrough Data Demonstrating Enhanced Stability and Solubility for Insulin, GLP-1s
Villya Pharmaceuticals has generated breakthrough stability and solubility data for formulations of insulin and GLP-1 peptides, including semaglutide, using its proprietary platform that complex non‑nutritive sugars with the peptides to create fully water‑soluble, highly stable solutions.
For insulin and GLP‑1 agonists, the new formulations show enhanced physical and chemical stability, better solubility, and simpler excipient profiles compared with conventional products, which rely on lipidation or complex buffers and stabilizers.
The improved stability and solubility are expected to support more flexible delivery options (including injectables, sublingual, and potentially oral routes), easier manufacturing, and the potential for reduced refrigeration needs, while maintaining bioactivity and receptor engagement.
Sources:
Villya Pharmaceuticals Submits Patent for 100% Water-Soluble ...
Choline‐Geranate Deep Eutectic Solvent Improves Stability and Half‐Life of Glucagon‐Like Peptide‐1
Villya Pharmaceuticals Revolutionizes Semaglutide with ...
Effect of Lipidation on the Structure, Oligomerization, and ... - PMC
CONTROLLED RELEASE OF BIOLOGICS FOR THE TREATMENT ...
Eli Lilly's Foundayo Enters GLP-1 Market - LinkedIn
Chem. Pharm. Bull. 56(2) 156-161 (2008)
WO2019038412A1 - Glp-1 compositions and uses thereof
Molecular engineering of safe and efficacious oral basal insulin
WO2019120480A1 - Solubility of glp-1 peptide - Google Patents
Designing GLP-1 delivery: structural perspectives and ...
Villya Pharmaceutical develops water-soluble Semaglutide
Observation of unique stable nano-assemblies of a lipidated ...